Meeting
2014 ASCO Annual Meeting
A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia.
Authors
Alexander Xenakis
CBPartners, New York, NY
Alexander Xenakis , Nathaniel Smith , Rachel Beckerman , Jagpreet Chhatwal , Stephanie A. Gregory , Javier Pinilla-Ibarz , Andrew Briggs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7101)
DOI
10.1200/jco.2014.32.15_suppl.7101
Abstract #
7101
Poster Bd #
386
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.
First Author: Wojciech Jurczak
Poster
2016 ASCO Annual Meeting
Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.
First Author: Jennifer R. Brown
Poster
2016 ASCO Annual Meeting
An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies.
First Author: Jacob Drobnyk Soumerai
Poster
2022 ASCO Annual Meeting
Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.
First Author: Jeff Porter Sharman